(vianews) - sanofi (san.pa) is among this list of stock assets with the highest dividend rate and return on equity on the drug manufacturers—general industry.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| sanofi (san.pa) | €101.68 | 3.49% | 11.77% |
| merck and co inc (mrk.pa) | €104.00 | 2.57% | 34.46% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. sanofi (san.pa)
3.49% forward dividend yield and 11.77% return on equity
sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the united states, europe, and internationally. it operates through pharmaceuticals, vaccines, and consumer healthcare segments. the company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. in addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis a, typhoid, cholera, yellow fever, and rabies vaccines. the company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. further, it has a collaboration and license agreement with exscientia to develop up to 15 novel small-molecule for oncology and immunology; abl bio, inc. to develop abl301 for parkinson's disease; blackstone life sciences to develop pivotal studies and clinical development program; and seagen inc. to design, develop, and commercialize antibody-drug conjugates for cancer. additionally, the company has a collaboration agreement with igm biosciences, inc. to develop, manufacture, and commercialize igm antibody; skyhawk therapeutics, inc to discover and develop novel small molecules; and amunix pharmaceuticals, inc for t-cell engagers and cytokine therapies. it also enters in a strategic collaboration with scribe therapeutics inc. to develop genome editing technologies; and co-promotion service agreement with provention bio, inc. for the commercialization of teplizumab. the company was formerly known as sanofi-aventis and changed its name to sanofi in may 2011. sanofi was founded in 1973 and is headquartered in paris, france.
earnings per share
as for profitability, sanofi has a trailing twelve months eps of €6.66.
pe ratio
sanofi has a trailing twelve months price to earnings ratio of 15.27. meaning, the purchaser of the share is investing €15.27 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.77%.moving average
sanofi's worth is way higher than its 50-day moving average of €92.29 and way above its 200-day moving average of €88.63.more news about sanofi.
2. merck and co inc (mrk.pa)
2.57% forward dividend yield and 34.46% return on equity
merck & co., inc. operates as a healthcare company worldwide. it operates through two segments, pharmaceutical and animal health. the pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. the animal health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. the company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. it has collaborations with astrazeneca plc; bayer ag; eisai co., ltd.; ridgeback biotherapeutics lp; and gilead sciences, inc. to jointly develop and commercialize long-acting treatments in hiv. merck & co., inc. was founded in 1891 and is headquartered in rahway, new jersey.
earnings per share
as for profitability, merck and co inc has a trailing twelve months eps of €5.23.
pe ratio
merck and co inc has a trailing twelve months price to earnings ratio of 19.89. meaning, the purchaser of the share is investing €19.89 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 34.46%.revenue growth
year-on-year quarterly revenue growth grew by 2.3%, now sitting on 59.28b for the twelve trailing months.
yearly top and bottom value
merck and co inc's stock is valued at €104.00 at 22:40 est, under its 52-week high of €109.00 and way above its 52-week low of €73.20.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, merck and co inc's stock is considered to be overbought (>=80).
more news about merck and co inc.